**BRAVECTO™ SATISFACTION GUARANTEE**

**12-WEEK FLEA AND TICK PROTECTION**

* 1 CHEW
* 0 WORRIES

If your clients are not achieving the level of flea and tick control that was desired, please call our team of flea and tick control experts to see if they qualify for our BRAVECTO Satisfaction Guarantee. Our team will work with you to ensure that your clients are satisfied. If not, Merck Animal Health will work with the attending veterinarian to ensure the pet owner is refunded for the purchase of BRAVECTO.

### Lack of Effectiveness

- Claims for lack of effectiveness cannot be made until 12 weeks following the initial treatment.
- There is a one-time offer for lack of effectiveness claims, and only one offer is granted per pet.
- Households of 6 or more dogs and/or cats are not eligible.
- The satisfaction guarantee does not cover any other costs, including but not limited to those associated with the control of fleas/ticks, the treatment of flea/tick-borne diseases, medical treatments or procedures, including treatment of Flea Allergy Dermatitis.

### Palatability/Ingestion

- BRAVECTO is highly palatable. For pets unable to be dosed with BRAVECTO, Merck Animal Health will work with the veterinarian to ensure the pet owner is refunded for the purchase of BRAVECTO.
- For maximum effectiveness, it is recommended to re-dose any pet that vomits within 3 hours of receiving BRAVECTO. Merck Animal Health can send a replacement chew to the veterinarian for re-dosing (limit of 2 replacements per pet).

### Eligibility Requirements and Specifics of the Program

- An established veterinary-client-patient relationship must exist and the product must have been prescribed by, and purchased through, a licensed veterinarian.
- BRAVECTO must be used according to label directions.
- All pets in the household must be treated with an approved flea/tick product while BRAVECTO is in use. Untreated pets may harbor a flea infestation.
- An itemized receipt for the purchase of BRAVECTO from a veterinarian must be submitted to Merck Animal Health. The receipt must show the owner’s name, the pets’ name(s), place of purchase, date of purchase (which must be within the last 12 months), quantity purchased, product brand name, and purchase price.
- If multiple doses were purchased for multiple pets, but are only indicated for one pet on the receipt, the hospital staff will be asked to note this on the receipt.
- Merck Animal Health reserves the right to cancel or amend the Satisfaction Guarantee program at any time.

*Bravecto kills fleas, prevents flea infestations, and kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks. Bravecto also kills lone star ticks for 8 weeks.*

**IMPORTANT SAFETY INFORMATION:** The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. Bravecto is not effective against lone star ticks beyond 8 weeks after dosing.


Please see reverse side for full Prescribing Information.
Bravecto_4x8.5_K_w_color MAH.indd   3
141487 R2

Adverse Reactions: In a well-controlled U.S. field study, which included 294 dogs (224 dogs were administered Bravecto every 12 weeks and 70 dogs were administered an oral active control every 4 weeks and were provided with a tick collar), there were no serious adverse reactions. All potential adverse reactions were recorded in dogs treated with Bravecto over a 162-day period and in dogs treated with the active control over an 84-day period. The most frequently reported adverse reaction in dogs in the Bravecto and active control groups was vomiting.

Percentage of Dogs with Adverse Reactions in the Field Study

<table>
<thead>
<tr>
<th>Adverse Reaction (AR)</th>
<th>Bravecto Group: Percentage of Dogs with the AR During the 182-Day Study (n=224 dogs)</th>
<th>Active Control Group: Percentage of Dogs with the AR During the 84-Day Study (n=70 dogs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>7.1</td>
<td>14.3</td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>6.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4.9</td>
<td>2.9</td>
</tr>
<tr>
<td>Lethargy</td>
<td>5.4</td>
<td>7.1</td>
</tr>
<tr>
<td>Polydipsia</td>
<td>1.8</td>
<td>4.3</td>
</tr>
<tr>
<td>Fluorance</td>
<td>1.3</td>
<td>3.0</td>
</tr>
</tbody>
</table>

In a well-controlled laboratory dose confirmation study, one dog developed edema and hyperemia of the upper lips within one hour of receiving Bravecto. The edema improved progressively through the day and had resolved without medical intervention by the next morning.

For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318. Additional information can be found at www.bravecto.com. For information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

Animal Safety: Margin of Safety Study: In a margin of safety study, Bravecto was administered orally to 8- to 9-week-old puppies at a dose of up to 168 mg/kg (equivalent to 3X the maximum label dose) on three to four occasions at 8-week intervals. The dogs in the control group (DX) were untreated. There were no clinically-relevant, treatment-related effects on physical examinations, body weights, food consumption, clinical pathology (hematology, clinical chemistries, coagulation tests, and urinalysis), gross pathology, histopathology, or organ weights. Diarrhea, mucoid and bloody feces were the most common observations in this study, occurring at a similar incidence in the treated and control groups. Five of the twelve treated dogs that experienced one or more of these signs did so within 6 hours at the first dosing. One dog in the DX treatment group was observed to be dull, inappetant, with evidence of bloody diarrhea, vomiting, and weight loss beginning five days after the first treatment. One dog in the DX treatment group vomited food 4 hours following the first treatment.

Reproductive Safety Study: Bravecto was administered orally to intact, reproductively-sound male and female Beagles at a dose of up to 168 mg/kg (equivalent to 3X the maximum label dose) on three to four occasions at 8-week intervals. The dogs in the control group (DX) were untreated. There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs), and histopathology findings (adult dogs and puppies). One adult treated dog suffered a seizure during the course of the study (44 days after the second treatment). Abnormal salivation was observed on 17 occasions; in six treated dogs (11 occasions) after dosing and four control dogs (6 occasions). The following abnormalities were noted in 7 pups from 2 of the 10 dams in only the treated group during gross necropsy examination: limb deformity (4 pups), enlarged heart (2 pups), enlarged spleen (3 pups), and cleft palate (2 pups). During veterinary examination at Week 7, two pups from the control group had inguinal testicles, and two and four pups from the treated group had inguinal and cryptorchid testicles, respectively. No undescended testicles were observed at the time of necropsy (days 50 to 71).

Adverse Reactions: In a well-controlled field study Bravecto was used concurrently with other medications, such as vaccines, antimicrobials, and steroids. No adverse reactions were observed from the concurrent use of Bravecto with other medications.

Storage Information: Do not store above 86°F (30°C).

How Supplied: Bravecto is available in five strengths (112.5, 250, 500, 1000, and 1400 mg fluralaner per chew). Each chew is packaged individually into aluminum foil blister packs sealed with a peelable paper backed foil lid stock. Product may be packaged in 1, 2, or 4 chews per package.

NADA 141-426, Approved by FDA
Distributed by: Intervet Inc (d/b/a Merck Animal Health)
Summit, NJ 07901
Made in Austria
Copyright © 2014 Intervet Inc, a subsidiary of Merck & Company Inc.
All rights reserved
141487 R2